FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma By Ogkologos - May 23, 2025 600 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study AK105-304 and Study AK105-202 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR How Your Primary Care Provider Can Help You Throughout Your Cancer... March 5, 2021 How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find... May 21, 2020 New Technology System Allows Patients To Get A Mammogram And Biopsy... June 30, 2020 Many Men with Metastatic Prostate Cancer Are Not Getting the Recommended... February 18, 2025 Load more HOT NEWS Triple negative breast cancer drug given initial ‘no’ for NHS in... Oncotype DX Breast Cancer Test May Be Less Accurate for Black... Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients... Taking pride in all of our researchers
